Crossject (PA:ALCJ) — Market Cap & Net Worth
Market Cap & Net Worth: Crossject (ALCJ)
Crossject (PA:ALCJ) has a market capitalization of $82.54 Million (€70.61 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #20041 globally and #305 in its home market, demonstrating a -4.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crossject's stock price €1.33 by its total outstanding shares 53246686 (53.25 Million). Also see Crossject asset portfolio for a full breakdown of the balance sheet.
Crossject Market Cap History: 2015 to 2026
Crossject's market capitalization history from 2015 to 2026. Data shows change from $609.37 Million to $82.54 Million (-9.31% CAGR). Also see cash flow conversion of Crossject for how efficiently the company converts equity into cash flow.
Index Memberships
Crossject is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$41.14 Billion | 0.20% | #21 of 34 |
Weight: Crossject's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Crossject Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crossject's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALCJ stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
33.58x
Crossject's market cap is 33.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $266.34 Million | $1.42 Million | -$6.66 Million | 187.21x | N/A |
| 2017 | $275.09 Million | $3.23 Million | -$7.61 Million | 85.05x | N/A |
| 2018 | $73.99 Million | $2.44 Million | -$10.71 Million | 30.27x | N/A |
| 2019 | $141.12 Million | $500.00K | -$7.17 Million | 282.23x | N/A |
| 2020 | $188.05 Million | $4.84 Million | -$9.84 Million | 38.82x | N/A |
| 2021 | $174.86 Million | $912.00K | -$10.81 Million | 191.74x | N/A |
| 2022 | $203.33 Million | $954.00K | -$11.16 Million | 213.13x | N/A |
| 2023 | $306.69 Million | $145.00K | -$8.64 Million | 2115.07x | N/A |
| 2024 | $138.20 Million | $4.12 Million | -$12.79 Million | 33.58x | N/A |
Competitor Companies of ALCJ by Market Capitalization
Companies near Crossject in the global market cap rankings as of September 20, 2026. Review Crossject tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Crossject by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #179 globally with a market cap of $132.26 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #366 globally with a market cap of $75.25 Billion USD ( €64.36 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #422 globally with a market cap of $67.43 Billion USD ( €57.68 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #546 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #179 | Intuitive Surgical Inc | NASDAQ:ISRG | $132.26 Billion | $393.33 |
| #366 | EssilorLuxottica S. A. | PA:EL | $75.25 Billion | €139.00 |
| #422 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $67.43 Billion | €68.50 |
| #546 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Crossject Historical Marketcap From 2015 to 2026
Between 2015 and today, Crossject's market cap moved from $609.37 Million to $ 82.54 Million, with a yearly change of -9.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €82.54 Million | -39.45% |
| 2025 | €136.33 Million | -1.35% |
| 2024 | €138.20 Million | -54.94% |
| 2023 | €306.69 Million | +50.83% |
| 2022 | €203.33 Million | +16.28% |
| 2021 | €174.86 Million | -7.01% |
| 2020 | €188.05 Million | +33.26% |
| 2019 | €141.12 Million | +90.72% |
| 2018 | €73.99 Million | -73.10% |
| 2017 | €275.09 Million | +3.28% |
| 2016 | €266.34 Million | -56.29% |
| 2015 | €609.37 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Crossject was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.54 Million USD |
| MoneyControl | $82.54 Million USD |
| MarketWatch | $82.54 Million USD |
| marketcap.company | $82.54 Million USD |
| Reuters | $82.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more